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Zenith abdominal aortic aneurysm endovascular
graft
Roy K. Greenberg, MD,a Timothy A. M. Chuter, MD,b Richard P. Cambria, MD,c
W. Charles Sternbergh III, MD,d and Neal E. Fearnot, PhD,e Cleveland, Ohio; San Francisco, Calif; Boston,
Mass; New Orleans, La; and West Lafayette, Ind
Purpose: The safety and efficacy of the Zenith (Cook Inc, Bloomington, Ind) endovascular graft was assessed based on the
United States multicenter trial through 5 years of follow-up.
Methods: Between 2000 and 2003, the pivotal study enrolled patients to open surgery (control) or the Zenith endovascular
graft (endovascular). A separate continued access study arm enrolled endovascular patients using the same inclusion/exclusion
criteria. Both studieswere designed for 2-year follow-up, and the pivotal endovascular patients had the option of extending the
study follow-up through 5 years. All endovascular patients were stratified by physiologic risk into high-risk and standard-risk
groups to assess overall mortality, rupture, conversion, endoleaks, secondary interventions, and sac enlargement. The entire
endovascular cohort was pooled to assess device integrity, limb occlusion, component separation, and migration. The
suboptimal endovascular result (SER) was established as an end point to assess late adverse outcomes. Statistical analyses
included Kaplan-Meier estimations and Cox regression to assess factors contributing to sac enlargement and SER.
Results: The study enrolled 739 endovascular patients (352 pivotal, 387 continued access); 158 patients in the pivotal study
reconsented to be followed up for 5 years. For the patients at standard and high risk at 5 years, the respective survival estimate
was 83% and 61%, aneurysm-related death was 2% and 4%, and freedom from rupture was 100% and 99.6%, respectively.
Cumulative risk of conversion, limb occlusion, migration>10mm, or component separation was<3% at 5 years. Cumulative
risk of late endoleak was 12% to 15%, representing the primary indication for secondary interventions which occurred in 20%
of standard-risk patients and 25% of high-risk patients through 5 years. Sac enlargement was very rare and associated with
advanced age and larger aneurysms. SER was predicted by advanced age and internal iliac artery occlusion.
Conclusion: These middle- and long-term data support long-term durability of the Zenith endovascular graft. Risk of
aneurysm-related death or rupture was exceptionally low, and complications of migration, limb occlusion, and device
integrity issues were uncommon. Incidence of late endoleaks and association of endoleaks with sac growth underscore the
need for long-term follow-up of patients treated with endovascular grafts, although the sequelae of such events are
unknown. (J Vasc Surg 2008;48:1-9.)Long-term results after endovascular aneurysm repair
are essential to affirm durability of the intent to diminish
risk of rupture and aneurysm-related death. The continu-
ous evolution of implant design during the course of clin-
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doi:10.1016/j.jvs.2008.02.051ical trials may affect the relevance of long-term data. Unlike
most other commercially available stent grafts, the Zenith
device (Cook Inc, Bloomington, Ind) has undergone re-
markably few changes since its introduction in 1997. Nev-
ertheless, there is a paucity of published information on the
long-term performance of the current device. Reports from
Australia have included data on predicate designs,1 and
only two centers in theUnited States (US) had access to the
Zenith stent graft before the US pivotal ZenithMulticenter
Trial (ZMT) in 2000.2 The primary end point of this study
was a comparison of the morbidity between the surgical
control arm and the standard-risk endovascular arm at 30
days and at 1 year. The initial analysis of the pivotal trial was
reported in 2004, shortly after the device was approved for
commercial use in the United States.3
In addition to the initial ZMT report, several analyses
have further delineated the device performance in a variety
of patient populations. These include an assessment of late
complications,4 the effects of the suprarenal stent on renal
function,5 stent graft oversizing on neck dilation,6 gender
on overall outcome,7 large iliac limb diameters on iliac
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effect of physiologic risk and challenging anatomic factors
were also evaluated with regard to morphologic out-
comes,10 and other reports assessed a variety of factors and
late outcomes in the context of other endovascular
grafts.11-13
The infrarenal device used in the ZMT construct has
also become a platform to develop endovascular grafts to
treat more complex aneurysms, including devices with fen-
estrations intended to allow the treatment of juxtare-
nal14,15 and thoracic aneurysms,16 and branched devices
used to treat thoracoabdominal aneurysms.17-19 Design
modifications have allowed for the ability to preserve ante-
grade internal iliac arterial flow in the setting of common
iliac aneurysms.20-22 We analyzed later outcomes (up to 5
years) of infrarenal aneurysms treated in the US pivotal
study with the initial infrarenal device construct and also in
a continued access study that enrolled patients using iden-
tical inclusion/exclusion criteria and stratification regimen.
Patients in the pivotal study were monitored for up to 5
years, and patients in the continued access study were
monitored to 2 years. In this article we report the extended
follow-up data from both the pivotal and continued access
studies.
MATERIAL AND METHODS
The US Zenith abdominal aortic aneurysm (AAA) En-
dovascular Graft pivotal study was a 2-year controlled trial
that enrolled 432 patients who were treated with open
surgery (control) or the Zenith endovascular graft (endo-
vascular); the latter group was stratified by physiologic risk
into high-risk and standard-risk groups. The details of the
study design, high-risk criteria, and inclusion and exclusion
criteria were previously published.3 The primary study end
point was a comparison of the morbidity between the
surgical control arm and the standard-risk endovascular
arm at 30 days and 1 year. The device received US Food
and Drug Administration (FDA) approval in May 2003.
Patient enrollment after the pivotal cohort was allowed
within a separate continued access study arm, within which
patients were enrolled with the same inclusion and exclu-
sion criteria and allocated into high- and standard-risk
groups, in a manner identical to that in the pivotal study.
However, sites participating in the continued access arm of
the trial were not required to submit preoperative films for
review and sizing to a centralized site, providing an avenue
for greater implanting physician independence. After de-
vice approval, pivotal patients were given the option of
extending the study follow-up through 5 years, whereas
continued-access patients were monitored for only 2 years.
All participating patients were required to sign an in-
formed consent document approved by the respective in-
stitutional review boards. A core laboratory was responsible
for the independent assessment of all imaging studies, and
a clinical events committee was responsible for review and
adjudication of all events reported during the course of the
trial. A data safety monitoring board reviewed the resultsaccording to an enrollment schedule and allowed the study
to progress to completion.
Enrollment criteria for the pivotal and continued access
studies were identical. Moreover, a statistical analysis
showed that data from the two studies were poolable
(Table I, online only). Patients in both studies were cate-
gorized into standard- and high-risk groups by fitness for
surgery (physiologic risk). For the purpose of data analysis,
it was assumed that a patient’s physiologic state would have
no bearing on outcomes such as device integrity, limb
occlusion, and component separation andmigration, which
definitively relate to long-term device performance. These
outcomes were assessed using pooled data from both risk
categories.
Outcomes considered physiologic risk–dependent in-
cluded death, rupture, conversion, endoleak, secondary
interventions, and sac enlargement. Indeed, differences in
outcomes with this device between patients at high and
standard physiologic risk have been previously published
with respect to survival,23 sac behavior, and endoleaks.10
For risk-dependent outcomes, the standard- and high-risk
groups were analyzed separately; however, data were still
combined from the pivotal and continued access studies.
Specific endovascular outcomes are reported in accor-
Zenith AAA Endovascular Graft Clinical Trial 
Combined Pivotal, Continued Access and Female Registry Cohorts 
High Risk 
(n = 287 enrolled,
of which 286 
received a device) 
Surgical Control 
(n = 80) 
Pivotal (n = 90) 
Standard Risk 
(n = 452 enrolled, of 
which 450 received 
a device) 
Continued Access 
(n = 120) 
Pivotal (n = 194) 
Continued Access 
(n = 181)
n = 76 
n = 39 
n = 183 
n = 119 
Approval based on 
1-year Pivotal study 
results of Standard 
Risk vs. Surgical 
Patients agreeing to 
participate in the 5-year 
follow-up study 
Pivotal patients eligible for 
5-year follow-up study 
Patients available for 
follow-up at 2 years 
Fig 1. Enrollment in the United States Zenith Multicenter Trial
(ZMT). The pivotal portion of the trial included 80 surgical
controls, 200 standard-risk endovascular patients, 100 high-risk
endovascular patients, and 52 patients allocated to the roll-in arm.
After pivotal enrollment was completed, continued access was
provided through a separate study arm. At the conclusion of the
2-year follow-up, pivotal patients were given the opportunity to
participate in an extended follow-up study carrying out annual
assessments through 5 years. The various categories of the trial
resulted in three fundamental patient groups: surgical controls,
standard-risk endovascular, and high-risk endovascular. For analy-
sis purposes, the roll-in, pivotal study, and continued access groups
were combined into conglomerate standard- and high-risk endo-
vascular groups, with a variable degree of follow-up. This flow
chart shows enrollment and follow-up details. AAA, Abdominal
aortic aneurysm.dance with the most recent version of the endovascular
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Aneurysm-related deaths included any patients who died
30 days of the primary procedure or any secondary pro-
cedure, and patients outside of that window whose deaths
were considered by the clinical events committee to be
potentially related to the procedure or device.
The methods for determining device migration are
detailed in a previously published article.25 For complete-
ness, both 5-mm and 10-mm cutoffs are reported. Device
integrity issues refer to holes in the fabric, separation (frac-
ture) of the barbs, and fractures of the z-stents. Endoleaks
were considered late occurring only if no endoleak had
been identified on postprocedural cross-sectional imaging
studies before the 6-month examination.
For this study, a conglomerate end point, termed the
suboptimal endovascular result (SER), was created with the
intention of assessing the risk that a potentially adverse
outcome would develop after endovascular repair. This end
point was intended to assess which patients derived any
benefit from scheduled follow-up visits or interventions.
This end point included AAA-related death, rupture, con-
version, migration 10 mm, limb thrombosis, the devel-
opment of a late endoleak, or the need for any aneurysm-
related secondary intervention. The early identification of
patients who are at risk for reaching this end point has
significant implications on the optimal follow-up protocols.
Data were managed by MED Institute, a Cook Group
company. All statistical analyses were performed using SAS
8.2 software (SAS Institute, Cary, NC). Standard tabula-
tions of data included means, standard deviations, and
percentages, where applicable. Poolability was determined
by comparing the continued access groups with the pivotal
trial groups. Kaplan-Meier life-tables were constructed to
assess for differences between the standard- and high-risk
patient cohorts and, where appropriate, for clinical and
imaging outcome variables.
Patients are censored at their last known date of follow-
up. For outcomes other than death, the last known date of
follow-up includes the date of death. A Cox regression
model was developed to determine the relationship be-
tween the time and occurrence of maximum measured
aneurysm enlargement and the relevant covariates of inter-
est included in the standard- and high-risk patient cohorts.
A similar Cox regression analysis was used to assess preop-
erative patient characteristics as potential predictors of the
time and occurrence of an SER. For both Cox analyses,
individual factors were first analyzed by a univariate model.
Individual factors with a value of P  .15 from the univar-
iate analysis were included in an additional multivariate
step-wise Cox regression analysis. A significance level of
P  .05 was used to identify significant results from both
univariate and multivariate analyses.
RESULTS
The study began in January 2000 and was completed in
June 2003 after the enrollment of 819 patients, of which 80
were standard-risk surgical controls. Of the 739 enrolled
endovascular patients, 736 underwent successful implanta-tion of a Zenith AAA stent graft, and three implantations
were aborted due to iliac artery morphology not appreci-
ated before the procedure. Two of these patients were
successfully treated with open repair, and one patient
elected to have no intervention for the AAA. At 2 years, 610
patients were alive and participating in the trial. Of the 88
patients who died, 7 had been converted, 1 did not receive
the device, and 33 were lost to follow-up. From the survi-
vors, 259 patients were candidates for the 5-year study, and
158 patients provided voluntary consent (Fig 1). The con-
tinued access group was considered to be poolable with the
pivotal trial group based on statistical analyses that demon-
strated only two differences between the groups, consisting
of a slightly higher incidence of myocardial infarctions and
lower incidence of prior aortic surgery in the pivotal study
group (Table I, online version only).
Death, rupture, and conversion. Table II provides a
detailed analysis of freedom from death, rupture, and con-
version through 5 years of follow-up. Fig 2 depicts Kaplan-
Meier plots for all-cause mortality. Not surprisingly, the
all-cause mortality rate was significantly higher in the high-
risk group (P .001). This was the only outcome in Table
II to show a significant difference between the physiologic
risk groups, although it is possible that differences were
obscured by the rarity of many of these events.
Only one rupture occurred in the entire study cohort.
The patient was successfully converted, as previously re-
ported.3 There were seven other conversions in the study,
two of which occurred after failed stent graft insertions (as
described previously). Two more conversions were per-
formed to treat infection detected between 1 and 2 years,
one conversion was for an additional visceral aortic aneu-
rysm, and one was done to address a persistent proximal
endoleak at 6 months. The only conversion that occurred
2 years resulted from late proximal neck dilation at 4 years
of follow-up.
Migration, component separation, limb occlusion,
and device integrity. Given that these adverse events were
considered to be independent of physiologic risk, all endo-
vascular patients were viewed as a conglomerate group.
Device migration was categorized into movement of 5 mm
and 10 mm, the latter of which relates to the endovascular
reporting standards and most other device trials.24 These
results are detailed in Table III. Only two cases of migration
of 10 mm occurred, both in the continued access group
at their concluding follow-up of 2 years. No migrations
10 mm occurred in the pivotal study throughout the 5
years. Of the 19 patients wheremigration between 5 and 10
mm was noted at any time point, none underwent second-
ary procedures associated with the migration, continued to
have migration, or had associated adverse events.
Component separation was rare, and only three pa-
tients experienced graft limb separation through 5 years. In
two cases, disconnection of the uncovered top stent from
the graft material necessitated placement of proximal exten-
sions with new uncovered proximal fixation systems.
Limb occlusions were also rare, with a cumulative risk
of 2.6% throughout the study course. Of note, all limb
plicab
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were seen between 2 and 5 years of follow-up.
Endoleaks, sac enlargement, and secondary inter-
ventions. Endoleak rates were analyzed separately for the
standard- and high-risk groups owing to potential differ-
ences between the physiologic risk groups10 and the poten-
tial for physiologic risk to influence the likelihood that a
Table II. Freedom from adverse endovascular events cate
expressed as Kaplan-Meier estimates, with standard errors
Group/exam period Rupture
High risk
1-month 1.000 (0)
(n  283)
(e  0)
(c  4)
12-month 0.996 (0.004)
(n  252)
(e  1)
(c  34)
24-month 0.996 (0.004)
(n  210)
(e  1)
(c  76)
36-month 0.996 (0.004)
(n  39)
(e  1)
(c  247)
48-month 0.996 (0.004)
(n  39)
(e  1)
(c  247)
60-month 0.996 (0.004)
(n  26)
(e  1)
(c  260)
Standard risk
1-month 1.000 (0)
(n  447)
(e  0)
(c  4)
12-month 1.000 (0)
(n  422)
(e  0)
(c  29)
24-month 1.000 (0)
(n  375)
(e  0)
(c  76)
36-month 1.000 (0)
(n  119)
(e  0)
(c  332)
48-month 1.000 (0)
(n  116)
(e  0)
(c  335)
60-month 1.000 (0)
(n  79)
(e  0)
(c  372)
n, patients at risk; e, cumulative events; c, cumulative censored; n/a, not appatient would undergo a secondary intervention. The re-ported incidence of primary endoleaks was exceptionally
low, and most were resolved by the 2-year time point.3
Details regarding late endoleaks are listed in Table II and
Fig 3. Most of these were type II endoleaks, and no
difference existed between the groups at standard and high
physiologic risk.
Kaplan-Meier estimates were used to assess the likeli-
ed by physiologic risk group (standard vs high risk) and
in the parentheses
Freedom from adverse event
Conversion AAA-death
0.997 (0.003) 0.990 (0.006)
(n  283) (n  283)
(e  1) (e  3)
(c  3) (c  1)
0.993 (0.005) 0.968 (0.010)
(n  252) (n  252)
(e  2) (e  9)
(c  33) (c  26)
0.988 (0.007) 0.964 (0.011)
(n  210) (n  210)
(e  3) (e  10)
(c  74) (c  67)
0.988 (0.007) 0.964 (0.011)
(n  39) (n  39)
(e  3) (e  10)
(c  245) (c  238)
0.988 (0.007) 0.964 (0.011)
(n  39) (n  39)
(e  3) (e  10)
(c  245) (c  238)
0.988 (0.007) 0.964 (0.011)
(n  26) (n  26)
(e  3) (e  10)
(c  258) (c  251)
0.998 (0.002) 0.993 (0.004)
(n  447) (n  447)
(e  1) (e  3)
(c  3) (c  1)
0.993 (0.004) 0.989 (0.005)
(n  422) (n  422)
(e  3) (e  5)
(c  26) (c  24)
0.991 (0.005) 0.984 (0.006)
(n  375) (n  375)
(e  4) (e  7)
(c  72) (c  69)
0.991 (0.005) 0.978 (0.009)
(n  119) (n  119)
(e  4) (e  8)
(c  328) (c  324)
0.991 (0.005) 0.978 (0.009)
(n  116) (n  116)
(e  4) (e  8)
(c  331) (c  327)
0.982 (0.010) 0.978 (0.009)
(n  79) (n  79)
(e  5) (e  8)
(c  367) (c  364)
le.goriz
listedhood of freedom from sac enlargement and freedom from
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presumed causes of sac enlargement and the indication for
any secondary intervention are listed in Table IV. Certain
differences were noted with respect to morphologic out-
come stratified by physiologic risk. A log-rank test showed
a greater risk of late sac enlargement in high-risk patients.
Specific factors that may have contributed to this effect
Table II. Continued
Freedom fro
Death Late endoleak
0.990 (0.006) n/a
(n  283)
(e  3)
(c  1)
0.912 (0.017) 0.964 (0.013)
(n  252) (n  172)
(e  25) (e  7)
(c  10) (c  92)
0.815 (0.023) 0.959 (0.014)
(n  210) (n  111)
(e  51) (e  8)
(c  26) (c  152)
0.682 (0.039) 0.959 (0.014)
(n  39) (n  26)
(e  66) (e  8)
(c  182) (c  237)
0.682 (0.039) 0.920 (0.040)
(n  39) (n  22)
(e  66) (e  9)
(c  182) (c  240)
0.612 (0.048) 0.859 (0.070)
(n  26) (n  13)
(e  70) (e  10)
(c  191) (c  248)
0.993 (0.004) n/a
(n  447)
(e  3)
(c  1)
0.964 (0.009) 0.972 (0.008)
(n  422) (n  344)
(e  16) (e  11)
(c  13) (c  88)
0.908 (0.014) 0.947 (0.012)
(n  375) (n  251)
(e  40) (e  19)
(c  36) (c  173)
0.860 (0.020) 0.917 (0.019)
(n  119) (n  94)
(e  51) (e  23)
(c  281) (c  326)
0.853 (0.021) 0.907 (0.022)
(n  116) (n  76)
(e  52) (e  24)
(c  283) (c  343)
0.830 (0.024) 0.879 (0.029)
(n  79) (n  46)
(e  55) (e  26)
(c  317) (c  371)were then assessed with a Cox regression model (Table V,online version only). Individual factors conducive to in-
creased risk of sac enlargement (P  .05) included ad-
vanced age, lower body weight, female sex, larger initial
aneurysm size, presence of cancer, and inclusion in the
high-risk cohort. Anticoagulation status (aspirin, clopi-
dogrel or warfarin) was not a factor associated with an
increased risk of enlargement. An additional analysis with a
verse event
econdary intervention Aneurysm enlargement
0.972 (0.010) 1.000 (0)
(n  276) (n  210)
(e  8) (e  0)
(c  3) (c  0)
0.906 (0.018) 0.990 (0.007)
(n  230) (n  195)
(e  26) (e  2)
(c  31) (c  13)
0.867 (0.021) 0.959 (0.015)
(n  151) (n  120)
(e  35) (e  7)
(c  101) (c  83)
0.836 (0.031) 0.877 (0.041)
(n  30) (n  29)
(e  37) (e  12)
(c  220) (c  169)
0.752 (0.054) 0.784 (0.063)
(n  27) (n  22)
(e  40) (e  15)
(c  220) (c  173)
0.752 (0.054) 0.784 (0.063)
(n  18) (n  14)
(e  40) (e  15)
(c  229) (c  181)
0.971 (0.008) 1.000 (0)
(n  434) (n  372)
(e  13) (e  0)
(c  4) (c  0)
0.900 (0.014) 0.997 (0.003)
(n  381) (n  354)
(e  44) (e  1)
(c  26) (c  17)
0.876 (0.016) 0.972 (0.009)
(n  282) (n  257)
(e  54) (e  9)
(c  115) (c  106)
0.822 (0.024) 0.952 (0.014)
(n  98) (n  104)
(e  62) (e  13)
(c  291) (c  255)
0.805 (0.026) 0.933 (0.019)
(n  93) (n  90)
(e  64) (e  15)
(c  294) (c  267)
0.805 (0.026) 0.922 (0.022)
(n  61) (n  48)
(e  64) (e  16)
(c  326) (c  308)m ad
Smultivariate step-wise Cox regression model revealed that
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joint predictors of an increased risk of sac enlargement.
Suboptimal endovascular result analysis. Individual
factors related to increased risk of SER were evaluated with
a Cox regressionmodel (Table VI, online only). The factors
predictive of increased risk of SER (P  .05) included
advanced age, presence of iliac involvement in the aneu-
rysm, internal iliac artery occlusion, and smaller neck diam-
eter. An additional multivariate step-wise Cox regression
Fig 2. Kaplan-Meier graph shows mortality stratified by stan-
dard-risk (black line) and high-risk (red line) physiologic groups.
Error bars represent 95% confidence intervals at each time point.
Table III. Pooled data (standard- and high-risk groups) f
Kaplan-Meier estimates, with standard errors listed in the p
Exam period Limb occlusion Migration 5 mm Migration
1-month 0.988 (0.004) n/a n/
(n  721)
(e  9)
(c  9)
12-month 0.981 (0.005) 0.995 (0.003) 0.999 (0
(n  662) (n  568) (n  5
(e  14) (e  3) (e  1
(c  63) (c  145) (c  1
24-month 0.974 (0.006) 0.977 (0.007) 0.999 (0
(n  494) (n  400) (n  4
(e  18) (e  12) (e  1
(c  227) (c  304) (c  3
36-month 0.974 (0.006) 0.955 (0.012) 0.996 (0
(n  155) (n  128) (n  1
(e  18) (e  17) (e  2
(c  566) (c  571) (c  5
48-month 0.974 (0.006) 0.955 (0.012) 0.996 (0
(n  152) (n  110) (n  1
(e  18) (e  17) (e  2
(c  569) (c  589) (c  6
60-month 0.974 (0.006) 0.935 (0.019) 0.996 (0
(n  106) (n  71) (n  7
(e  18) (e  19) (e  2
(c  615) (c  626) (c  6n, patients at risk; e, cumulative events; c, cumulative censored; n/a, not applicabmodel showed that advanced age and internal iliac artery
occlusion are joint predictors of an increased risk of SER.
DISCUSSION
The initial report of the ZMT provided evidence that
endovascular repair of AAA with amenable anatomy was
superior to open surgery for both associated morbidities
and aneurysm-related death.3 The conclusions were tem-
pered by the expectation that endovascular repair would
require more detailed follow-up than open repair and
might not provide as durable a result. The data presented in
this article extend our confidence regarding longer-term
durability of endovascular repair with the Zenith AAA
device through 5 years. The observation in 736 implants of
only a single rupture (at 6 months), a freedom from open
surgical conversion of98%, and freedom from aneurysm-
related death of 98% in standard-risk patients and 96% in
high-risk patients support the long-term durability of this
device. Yet as with most evaluations of endovascular treat-
ments, it is the detailed analysis that will provide clues of
whether a sustained benefit can be expected.
Regretfully, we have no data on the surgical control
group beyond 1 year, precluding any long-term compari-
sons against surgical controls. Several previously reported
adverse endovascular outcomes, such as limb thrombosis,
stent fracture, and component separation, were so uncom-
mon that further statistical analyses seeking causative fac-
tors or effect were not fruitful. However, other observa-
mplications relating to the stent graft expressed as
theses
om from event
mm Barb separation Stent fracture Component separation
1.000 (0) 1.000 (0) 1.000 (0)
(n  705) (n  705) (n  705)
(e  0) (e  0) (e  0)
(c  26) (c  26) (c  26)
) 0.994 (0.003) 1.000 (0) 1.000 (0)
(n  583) (n  587) (n  587)
(e  4) (e  0) (e  0)
(c  144) (c  144) (c  144)
) 0.980 (0.006) 0.998 (0.002) 0.994 (0.03)
(n  402) (n  410) (n  408)
(e  11) (e  1) (e  3)
(c  318) (c  320) (c  320)
) 0.965 (0.010) 0.993 (0.006) 0.991 (0.04)
(n  132) (n  137) (n  137)
(e  15) (e  2) (e  4)
(c  584) (c  592) (c  590)
) 0.935 (0.018) 0.985 (0.010) 0.977 (0.011)
(n  115) (n  123) (n  123)
(e  19) (e  3) (e  6)
(c  597) (c  605) (c  602)
) 0.918 (0.021) 0.968 (0.015) 0.977 (0.011)
(n  69) (n  72) (n  72)
(e  21) (e  5) (e  6)
(c  641) (c  654) (c  653)or co
aren
Freed
10
a
.001
68)
)
47)
.001
00)
)
15)
.003
28)
)
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)
04)
.003
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interventions merit further discussion.
The Zenith endovascular graft has shown good long-
term device durability in this study. Component separation
was rare: Only three patients experiencing graft limb sepa-
ration through 5 years. In two cases, the uncovered top
stent had disconnected from the graft material, which
required placement of proximal extensions with new un-
covered proximal fixation systems. These occurrences,
along with a small number of cases in Europe and Australia,
were responsible for a design modification in 2002 to
double the suture-mediated attachment between the top
stent and the proximal margin of the graft. None of the
modified devices in the continued access arm have shown
signs of top stent disconnection.
Barb separationswere also noted andpreviously reported3
and still have not been associated with any clinical sequelae.
Subsequent to this study, the barbs were increased in
diameter—from 0.009 inches to 0.011 inches—to reduce
Fig 3. The incidence of both new and persistent endole
standard-risk (black) groups. The Kaplan-Meier plot sho
bars represent 95% confidence intervals at each time poin
standard-risk groups, although the numbers of patientsthe likelihood of separations.Minor device changes occurred after the conclusion of
the US trial and included an increased gap between the first
three z-stents to improve neck conformability, the addition
of a 36-mm-diameter device, and the implementation of a
hydrophilic-coated sheath and a modified valve (Captor
Valve, Cook) in an effort to improve delivery.
The overall incidence of endoleaks, sac enlargement,
and migration were favorable in comparison with other
multicenter device trials,26,27 with a low incidence of pri-
mary endoleaks and an overall incidence of late endoleaks of
4% at every annual time point. The risk of sac enlarge-
ment was approximately 1.6% for the standard-risk patients
at each annual time point, and the cumulative risk for
migration was 1% for all patients.
Type I and III endoleaks were notably absent after
correction of problems relating to the initial implantation.
As calculated from life-table estimates, 12% to 14% of the
patients are at risk for the development of late endoleaks5
years of implantation. Reassuringly, most late leaks in this
y type and time of onset is shown for high-risk (red) and
e cumulative risk for a late endoleak of any type. Error
statistical differences were noted between the high- and
follow-up time points were relatively small.aks b
ws th
t. Nostudy were type II in nature, but the mechanism by which
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occurred in an intermittent manner or simply were not
appreciated on earlier imaging studies, but those are un-
likely explanations for all late leaks. Alternatively, late type
II endoleaks may represent spontaneous recanalization of
lumbar or the inferior mesenteric arteries.
Although many endovascular enthusiasts consider type
II endoleaks entirely benign, ruptures relating to type II
endoleaks13 and the incontrovertible link between en-
doleaks and sac enlargement11 cannot be ignored. Of the
31 patients who experienced sac enlargement during the
trial, 25 were related to endoleaks (early or late), 80% of
which were type II in nature. Not surprisingly, the treat-
ment of early and late type II endoleaks accounts for about
two-thirds of all secondary interventions. The association
of sac enlargement with high physiologic risk has been
previously noted10 and is confirmed in this report. In
addition, a multivariate Cox regression analysis identified
advanced patient age and larger initial aneurysm size as
predictive factors for sac size enlargement. These observa-
tions merit further investigation.
The establishment of a conglomerate end point (SER)
representative of virtually any adverse late device event was
established in an effort to determine whether a subset of
Table IV. Data for patients that had evidence of
aneurysmal sac size increase (5 mm) or any secondary
intervention
Event No.
Aneurysm enlargement
Potential cause
Total patients, No. 31
Persistent endoleak
Type II 20
Other 5
Graft infection 2
Proximal neck dilation 1
Unidentified 3
Secondary interventions
Total 153
Conversion 8
Endoleak 96
Proximal type I 5
Distal type I 10
Type IIa 67
Type III 11
Multiple 3
Graft kink, limb stenosis or occlusion 21
Top stent detachment 2
Renal (angiography, angioplasty or stenting) 14
Distal embolization 2
Other 10
Peripheral vascular 7
Thoracic dissection 1
Thrombosis of dialysis graft 1
Diagnostic Angiogram for Endoleak 1
aType II endoleaks were the most frequent etiology of enlargement and the
most common secondary intervention. The need for such interventions and
method by which they were done was left to the discretion of the treating
physician.patients could be identified requiring vigilant follow-up,while patients unlikely to present with events might have a
more relaxed follow-up schedule. The freedom from a SER
was then calculated, and factors contributing to the likeli-
hood of a SER were assessed. Advanced age and internal
iliac artery occlusion were noted to be significant preoper-
ative factors linked to a SER.
The primary study weaknesses relate to the nonran-
domized design, the limited number of patients consenting
to 5 years of follow-up, and the lack of long-term follow-up
for all control (open surgical) patients. These study design
issues preclude firm conclusions regarding the superiority
of endovascular repair compared with open repair. Further-
more, the limited number of patients followed up out to 5
years also restricts the power of our statistical analyses. It is
possible that if detailed, monitored, core lab data were
available on a greater number of patients, our assessment of
SER could provide the ability to suggest scientifically sup-
ported follow-up paradigms. Consideration has been given
to further studies in these areas.
CONCLUSIONS
Overall, the longer-term results reported in this study
support the use of the Zenith AAA Endovascular Graft in
patients amenable to open surgical repair, as well as those
considered to be at high-physiologic risk. The lack of late
ruptures, small number of conversions, and low risk of
migration, limb thrombosis, component separation, and
stent fracture relate to the integrity of the implant con-
struct, proper patient selection, and the technical abilities of
our investigators. Sac behavior and late endoleak incidence,
although generally favorable, mandate continued follow-
up. The occurrence of late endoleaks and persistent sac
enlargement in a subset of patients treated with endovas-
cular AAA repair will require further investigation. The
application of the Zenith endovascular graft to infrarenal
aneurysms with appropriate anatomy is associated with a
very low risk of failure 5 years and thus provides a prom-
ising platform for future developments.
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